Icon

VIGAMOX (nda021598)- (EQ 0.5% BASE)

MOXIFLOXACIN HYDROCHLORIDE HARROW EYE
EQ 0.5% BASE
Yes No
2020-Mar-29 Expired
None None
None No
VIGAMOX is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, Streptococcus viridans group, Acinetobacter lwoffii, Haemophilus influenzae, Haemophilus parainfluenzae, Chlamydia trachomatis
11 1 10
Total Other Developers 12
Drugs with Suitability No
EQ 0.5% BASE ** ** Up - 6
NDA Sales Available Total Generic Sales Available
Yes 8
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** ***. *********** *** ***** ***** **** ****, ******** ****, ******* *** ***, ****** (***) ***
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ***** *** ***** ******* *********** ****-*, **** **. *-* *** *-*-*, ******* ******** **** ***** **, ****. ****, ******* ****, ****. ****, *********, ****** ******* ******, ***** (***) ***
****** **** ****** *** ***** ********* ******* *** (*** *****) *********** ** ******** *** *** *, ********, *** ****** (**) *****-****, ****** ****** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ****** ******** ****** ******* ******* *** *********** ****-**, ****** **. ** & **, ************* ******* ***- *********, ******** ******, **********, ********* ******, ***** (***) ***
****** ******* ********** ***** **** ******* *********** ***-***, ** *****, ****** **** ****, *****, *********** ********** ****, *********, ********* ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ******* ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ******** ***, **** **. ****/****, ******* - *********, ****** - *****, ********, ******* ******, ***** (***) ***
****** ******** ******* *** ******** ************ ******* ******* *********** **/*, ******** ******* *********** *****, *********, ********* ******, ***** (***) ***
****** ******* ****** ******* ****** ******* *********** ****-***, ******* *****, ****** **** ****, ***. ****** *******, ****** *****, *******, ******** ******* ******, ***** (***) ***

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.